Effect of Pravastatin on Kidney Function in Patients with Dyslipidemia and Type 2 Diabetes Mellitus: A Multicenter Prospective Observational Study.

Autor: Kim HJ; Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, Korea., Hur KY; Division of Endocrinology and Metabolism, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea., Lee YH; Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea., Kim JT; Department of Internal Medicine, Eulji University College of Medicine, Seoul, Korea., Lee YK; Division of Nephrology, Department of Internal Medicine, NHIC Ilsan Hospital, Goyang, Korea., Baek KH; Division of Endocrinology and Metabolism, Department of Internal Medicine, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea., Choi EJ; Division of Nephrology, Department of Internal Medicine, Bucheon St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea., Hwang WM; Division of Nephrology, Department of Internal Medicine, Konyang University Hospital, Daejeon, Korea., Bang KT; Department of Internal Medicine, Eulji University School of Medicine, Daejeon, Korea., Lim JS; Division of Endocrinology and Metabolism, Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju Severance Christian Hospital, Wonju, Korea., Chung YJ; Department of Internal Medicine, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Korea., Jo SR; Department of Internal Medicine, Changwon Fatima Hospital, Changwon, Korea., Oh JS; Division of Nephrology, Department of Internal Medicine, Bong Seng Memorial Hospital, Busan, Korea., Lee SH; Department of Internal Medicine, Inje University Busan Paik Hospital, College of Medicine, Inje University, Busan, Korea., Ko SH; Division of Endocrinology and Metabolism, Department of Internal Medicine, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea., Choi SH; Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, 82 Gumi-ro 173 Beon-gil, Bundang-gu, Seongnam, 13620, Korea. drshchoi@snu.ac.kr.
Jazyk: angličtina
Zdroj: Advances in therapy [Adv Ther] 2024 Aug; Vol. 41 (8), pp. 3119-3137. Date of Electronic Publication: 2024 Jun 16.
DOI: 10.1007/s12325-024-02862-5
Abstrakt: Introduction: Several studies have reported that pravastatin can mitigate the progression of kidney disease, but limited evidence exists regarding its effects on kidney function in Asian patients. This multicenter prospective observational study aimed to assess the effect of pravastatin on kidney function in Korean patients with dyslipidemia and type 2 diabetes mellitus (T2DM) in clinical practice.
Methods: This 48-week prospective multicenter study included 2604 of 2997 eligible patients with dyslipidemia and T2DM who had available estimated glomerular filtration rate (eGFR) measurements. The primary endpoint was eGFR percent change at week 24 from baseline. We also assessed secondary endpoints, which included percent changes in eGFR at weeks 12 and 48 from baseline, as well as changes in eGFR, metabolic profiles (lipid and glycemic levels) at 12, 24, and 48 weeks from baseline, and safety.
Results: We noted a significant improvement in eGFR, with mean percent changes of 2.5%, 2.5%, and 3.0% at 12, 24, and 48 weeks, respectively (all adjusted p < 0.05). The eGFR percent changes significantly increased in subgroups with baseline eGFR 30-90 mL/min/1.73 m 2 , glycated hemoglobin (HbA1c) ≥ 7 at baseline, no hypertension history, T2DM duration > 5 years, or previous statin therapy. Lipid profiles were improved and remained stable throughout the study, and interestingly, fasting glucose and HbA1c were improved at 24 weeks.
Conclusion: Our findings suggest that pravastatin may have potential benefits for improving eGFR in Korean patients with dyslipidemia and T2DM. This could make it a preferable treatment option for patients with reduced kidney function.
Trial Registration Number: NCT05107063 submitted October 27, 2021.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: